AlphaStocks
5.2
Consider Buy

Moderna, Inc. (MRNA)

Health Care / Biotechnology

S&P 500

$48.76

Below average on several measures. Research carefully.

Consider Buy

Score based on 4 of 5 models — moderate confidence

#500out of 1126 in Health Care

Is Moderna, Inc. a Good Investment in 2026?

Moderna, Inc. (MRNA) scores 5.2 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model is the most favorable, rating Moderna, Inc. as Neutral. However, the Greenblatt Magic Formula model rates it Caution — Bottom half (rank 93%). Moderna, Inc. ranks #500 out of 1126 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

ROE-31.4Market Cap19B

Valuation

Currently unprofitable — fair value estimate not available.

Fair value estimate not available for this stock.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Neutral

3/9

Buffett

Caution

Business quality & competitive moat

Graham

Neutral

Price vs intrinsic value

Lynch

Limited Data

Growth rate vs price (PEG)

Greenblatt

Caution

Bottom half (rank 93%)

Frequently Asked Questions

Is Moderna, Inc. (MRNA) a good investment?
Based on AlphaStocks' composite analysis, Moderna, Inc. (MRNA) scores 5.2 out of 10, earning a Consider Buy rating. This score is below average, suggesting caution. Currently unprofitable — fair value estimate not available.
What is Moderna, Inc.'s Piotroski F-Score?
Moderna, Inc.'s Piotroski F-Score status is Neutral. The raw score is 3/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is MRNA overvalued or undervalued?
A precise fair value estimate is not available for MRNA. Currently unprofitable — fair value estimate not available.
How does MRNA compare to other Health Care stocks?
Moderna, Inc. ranks #500 out of 1126 stocks in the Health Care sector, placing it in the top 44% of its sector by composite score. This is an above-average position relative to sector peers.
What do investment models say about MRNA?
AlphaStocks evaluates MRNA using five proven investment models. Piotroski: Neutral; Buffett: Caution; Graham: Neutral; Greenblatt Magic Formula: Caution. These models are combined into a single composite score of 5.2/10.

Similar Stocks

PARRAZNFTI

Compare MRNA with

MRNA vs PARRMRNA vs AZNMRNA vs FTI

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer